Agios Pharmaceuticals Q2 revenue beats estimates

Agios Pharmaceuticals

31/07/2025 11:47

Overview

Agios Q2 2025 product revenue rises to $12.5 mln, beating analyst expectations

Co ends Q2 with $1.3 bln in cash, down from $1.5 bln at year-end 2024

Agios prepares for potential U.S. approval of PYRUKYND for thalassemia in Sept 2025

Outlook

Agios expects PYRUKYND approval for thalassemia by September 7, 2025

Result Drivers

PYRUKYND SALES - Generated $12.5 mln in Q2 2025, up from $8.6 mln in Q2 2024, driven by increased patient enrollment

EUROPEAN EXPANSION - Entered distribution agreement with Avanzanite Bioscience for PYRUKYND sales in European markets

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
Beat
$12.46 mln
$9.48 mln (8 Analysts)
Q2 EPS
-$1.93
Q2 Net Income
-$112.02 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Agios Pharmaceuticals Inc is $53.50, about 29.8% above its July 30 closing price of $37.54

Press Release: ID:nGNX8Q59wR

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)